

# Janet E Pope

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7889158/publications.pdf>

Version: 2024-02-01

603  
papers

35,843  
citations

4960

84  
h-index

4991

167  
g-index

616  
all docs

616  
docs citations

616  
times ranked

26379  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
4	Mortality in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 2550-2557.	6.7	924
5	Novel treatment strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017, 389, 2338-2348.	13.7	697
6	Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis. <i>New England Journal of Medicine</i> , 1997, 337, 382-388.	27.0	694
7	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 480-489.	0.9	671
8	CIP2A Inhibits PP2A in Human Malignancies. <i>Cell</i> , 2007, 130, 51-62.	28.9	662
9	Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. <i>Arthritis and Rheumatism</i> , 2004, 50, 3985-3993.	6.7	656
10	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1340-1349.	0.9	633
11	A Randomized Trial of Arthroscopic Surgery for Osteoarthritis of the Knee. <i>New England Journal of Medicine</i> , 2008, 359, 1097-1107.	27.0	614
12	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15002.	30.5	587
13	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	13.7	505
14	Highly Effective Visible-Light-Induced H <sub>2</sub> Generation by Single-Layer 1T-MoS <sub>2</sub> and a Nanocomposite of Few-Layer 2H-MoS <sub>2</sub> with Heavily Nitrogenated Graphene. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 13057-13061.	13.8	438
15	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.9	394
16	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2001, 44, 1351-1358.	6.7	361
17	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	10.7	348
18	An international cohort study of cancer in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 1481-1490.	6.7	333

#	ARTICLE	IF	CITATIONS
19	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
20	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	12.8	314
21	Psoriasis and Pustular Dermatitis Triggered by TNF- $\alpha$ Inhibitors in Patients With Rheumatologic Conditions. <i>Archives of Dermatology</i> , 2007, 143, 223-31.	1.4	291
22	Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001, 44, 1841-1847.	6.7	254
23	Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2012, 39, 1559-1582.	2.0	250
24	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
25	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.9	236
26	Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. <i>Rheumatology</i> , 2005, 44, 145-150.	1.9	194
27	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016, 32, S35-S65.	1.7	194
28	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. <i>Osteoarthritis and Cartilage</i> , 2002, 10, 506-517.	1.3	191
29	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
30	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. <i>Rheumatology</i> , 2011, 50, 762-767.	1.9	188
31	Treatment Algorithms for Systemic Sclerosis According to Experts. <i>Arthritis and Rheumatology</i> , 2018, 70, 1820-1828.	5.6	185
32	Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 353-361.	3.4	182
33	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
34	Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 269-277.	3.4	180
35	Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology</i> , 2010, 49, 1683-1693.	1.9	170
36	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-initiated, Multicenter, Double-blind, Randomized, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163

#	ARTICLE	IF	CITATIONS
37	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011, 27, 635-662.	1.7	160
38	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
39	<i>Campylobacter</i> Reactive Arthritis: A Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 48-55.	3.4	156
40	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1553-1568.	1.7	153
41	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. <i>Rheumatology</i> , 2010, 49, 2172-2180.	1.9	142
42	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	5.6	139
43	Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. <i>Lupus</i> , 2011, 20, 1345-1355.	1.6	138
44	Digital ulcers: overt vascular disease in systemic sclerosis. <i>Rheumatology</i> , 2006, 48, iii19-iii24.	1.9	137
45	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 1796-1804.	6.7	136
46	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
47	Health-related quality of life in systemic sclerosis: A systematic review. <i>Arthritis and Rheumatism</i> , 2009, 61, 1112-1120.	6.7	129
48	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 1479-1485.	6.7	128
49	The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review. <i>Journal of Rheumatology</i> , 2013, 40, 1545-1556.	2.0	127
50	Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1222-1228.	0.9	126
51	Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 179-185.	3.4	124
52	Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1653-1661.	3.4	123
53	Employment and work disability in systemic lupus erythematosus: a systematic review. <i>Rheumatology</i> , 2008, 48, 281-284.	1.9	122
54	Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety. <i>Journal of Rheumatology</i> , 2012, 39, 1583-1602.	2.0	122

#	ARTICLE	IF	CITATIONS
55	Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 738-745.	6.7	121
56	Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. <i>Rheumatology</i> , 2010, 49, 789-796.	1.9	118
57	Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry. <i>Arthritis Care and Research</i> , 2011, 63, 142-149.	3.4	118
58	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 519-524.	3.4	117
59	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021, 398, 803-816.	13.7	117
60	The Minimally Important Difference for the Health Assessment Questionnaire in Rheumatoid Arthritis Clinical Practice Is Smaller Than in Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2009, 36, 254-259.	2.0	115
61	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012, 51, 2204-2214.	1.9	115
62	Malnutrition Is Common in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group Database. <i>Journal of Rheumatology</i> , 2009, 36, 2737-2743.	2.0	114
63	Accuracy of Canadian Health Administrative Databases in Identifying Patients With Rheumatoid Arthritis: A Validation Study Using the Medical Records of Rheumatologists. <i>Arthritis Care and Research</i> , 2013, 65, 1582-1591.	3.4	114
64	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015, 42, 1767-1780.	2.0	113
65	The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multiethnic Cohort. <i>Journal of Rheumatology</i> , 2009, 36, 1200-1208.	2.0	111
66	The Diagnosis and Treatment of Raynaud's Phenomenon. <i>Drugs</i> , 2007, 67, 517-525.	10.9	110
67	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R50.	3.5	110
68	Prevalence of hearing loss in the United States by industry. <i>American Journal of Industrial Medicine</i> , 2013, 56, 670-681.	2.1	110
69	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	5.6	110
70	A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. <i>Medical Science Monitor</i> , 2011, 17, CR347-CR354.	1.1	110
71	Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails—A Consensus of Systemic Sclerosis Experts. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 42-55.	3.4	107
72	A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2014, 16, 435.	3.5	106

#	ARTICLE	IF	CITATIONS
73	Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. <i>Arthritis and Rheumatism</i> , 2011, 63, 3547-3551.	6.7	105
74	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	1.9	104
75	Clinical Features and Prognosis of Late-onset Systemic Lupus Erythematosus: Results from the 1000 Faces of Lupus Study. <i>Journal of Rheumatology</i> , 2010, 37, 38-44.	2.0	103
76	Meta-Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 1460-1471.	3.4	103
77	Polyautoimmunity and familial autoimmunity in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2008, 31, 156-159.	6.5	101
78	MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 870-877.	6.7	98
79	Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). <i>Arthritis Care and Research</i> , 2011, 63, S98-111.	3.4	98
80	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	7.4	95
81	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 219-229.	3.4	95
82	Association of C-reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2012, 64, 1405-1414.	3.4	93
83	All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. <i>Rheumatology</i> , 2013, 52, 905-909.	1.9	93
84	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015, 67, 1237-1245.	3.4	88
85	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 50-74.	1.2	87
86	Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 504-509.	6.7	86
87	Does the impact of board independence on large bank risks change after the global financial crisis?. <i>Journal of Corporate Finance</i> , 2017, 44, 149-166.	5.5	86
88	A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. <i>Archives of Internal Medicine</i> , 1993, 153, 477-484.	3.8	86
89	The Minimally Important Difference for the Fatigue Visual Analog Scale in Patients with Rheumatoid Arthritis Followed in an Academic Clinical Practice. <i>Journal of Rheumatology</i> , 2008, 35, 2339-2343.	2.0	85
90	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. <i>Osteoarthritis and Cartilage</i> , 2002, 10, 518-527.	1.3	84

#	ARTICLE	IF	CITATIONS
91	A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2007, 27, 77-83.	2.2	84
92	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1063-1070.	2.4	81
93	Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. <i>Arthritis Care and Research</i> , 2010, 62, 1181-1189.	3.4	79
94	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.9	79
95	Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 438-443.	6.7	77
96	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	3.4	77
97	Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatology International</i> , 2012, 32, 645-653.	3.0	76
98	Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 949-954.	0.9	76
99	Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. <i>The Cochrane Library</i> , 1998, , CD000953.	2.8	74
100	Development of a provisional core set of response measures for clinical trials of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 703-709.	0.9	74
101	Cigarette smoking in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 230-238.	6.7	74
102	A study of the frequency of pericardial and pleural effusions in scleroderma. <i>British Journal of Rheumatology</i> , 1998, 37, 1320-1323.	2.3	72
103	Requirement of transforming growth factor $\beta$ 1-activated kinase 1 for transforming growth factor $\beta$ 1-induced $\alpha$ -smooth muscle actin expression and extracellular matrix contraction in fibroblasts. <i>Arthritis and Rheumatism</i> , 2009, 60, 234-241.	6.7	72
104	Loss of PTEN Expression by Dermal Fibroblasts Causes Skin Fibrosis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1996-2003.	0.7	72
105	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 1345-1353.	3.4	72
106	Stand Up and Be Counted: Measuring and Mapping the Rheumatology Workforce in Canada. <i>Journal of Rheumatology</i> , 2017, 44, 248-257.	2.0	72
107	Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma. <i>Journal of Rheumatology</i> , 2009, 36, 323-329.	2.0	71
108	Sex Differences in Pain Scores and Localization in Inflammatory Arthritis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2012, 39, 1221-1230.	2.0	71

#	ARTICLE	IF	CITATIONS
109	Prognosis of Seronegative Patients in a Large Prospective Cohort of Patients with Early Inflammatory Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2361-2369.	2.0	71
110	Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. <i>Rheumatology</i> , 2017, 56, 1144-1153.	1.9	71
111	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
112	Mortality related to cerebrovascular disease in systemic lupus erythematosus. <i>Lupus</i> , 2006, 15, 835-839.	1.6	70
113	Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 409-417.	3.4	69
114	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3420-3429.	6.7	69
115	Antihomocitrullinated Fibrinogen Antibodies are Specific to Rheumatoid Arthritis and Frequently Bind Citrullinated Proteins/peptides. <i>Journal of Rheumatology</i> , 2014, 41, 270-279.	2.0	69
116	The development of rheumatoid arthritis after recombinant hepatitis B vaccination. <i>Journal of Rheumatology</i> , 1998, 25, 1687-93.	2.0	69
117	Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 270-278.	6.7	68
118	Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. <i>Lupus</i> , 2009, 18, 1281-1288.	1.6	68
119	A meta-analysis of the epidemiology of giant cell arteritis across time and space. <i>Arthritis Research and Therapy</i> , 2021, 23, 82.	3.5	68
120	Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada. <i>Arthritis Care and Research</i> , 2015, 67, 1047-1053.	3.4	67
121	Raynaud's phenomenon—an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019, 38, 3317-3330.	2.2	67
122	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. <i>Rheumatology</i> , 2014, 53, 1386-1394.	1.9	65
123	Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. <i>American Journal of Medicine</i> , 1991, 90, 299-309.	1.5	64
124	An update in pulmonary hypertension in systemic lupus erythematosus “do we need to know about it?”. <i>Lupus</i> , 2008, 17, 274-277.	1.6	64
125	Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic Conditions. <i>Journal of Rheumatology</i> , 2009, 36, 768-772.	2.0	64
126	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007, 34, 1194-200.	2.0	64



#	ARTICLE	IF	CITATIONS
127	Scleroderma overlap syndromes. <i>Current Opinion in Rheumatology</i> , 2002, 14, 704-710.	4.3	63
128	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. <i>Journal of Rheumatology</i> , 2014, 41, 2179-2185.	2.0	63
129	Office capillaroscopy in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007, 26, 1268-1274.	2.2	62
130	The cost of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 119-123.	6.7	62
131	Work Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 2481-2486.	2.0	61
132	Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 217-220.	1.1	61
133	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. <i>Arthritis and Rheumatology</i> , 2017, 69, 1871-1878.	5.6	61
134	Association of Smoking With Cutaneous Manifestations in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2013, 65, 1275-1280.	3.4	60
135	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
136	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015, 67, 582-587.	3.4	60
137	Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021, 48, 25-34.	2.0	60
138	Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2005, 32, 1273-8.	2.0	60
139	Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: Evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 966-973.	6.7	59
140	Update on Indices of Disease Activity in Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 93-98.	3.4	57
141	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 867-875.	6.7	56
142	Test-Retest Reliability of Patient Global Assessment and Physician Global Assessment in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 2178-2182.	2.0	56
143	The Minimally Important Difference for Patient Reported Outcomes in Systemic Lupus Erythematosus Including the HAQ-DI, Pain, Fatigue, and SF-36. <i>Journal of Rheumatology</i> , 2009, 36, 2231-2237.	2.0	56
144	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1003-1008.	0.9	56

#	ARTICLE	IF	CITATIONS
145	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018, 35, 1535-1563.	2.9	56
146	Management of Fatigue in Rheumatoid Arthritis. <i>RMD Open</i> , 2020, 6, e001084.	3.8	56
147	Expert Agreement on EULAR/EUSTAR Recommendations for the Management of Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 1326-1328.	2.0	54
148	Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 787-794.	2.0	54
149	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016, 2, e000225.	3.8	54
150	Variability of skin scores and clinical measurements in scleroderma. <i>Journal of Rheumatology</i> , 1995, 22, 1271-6.	2.0	54
151	Musculoskeletal involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2003, 29, 391-408.	1.9	53
152	Cervical spine involvement in rheumatoid arthritis over time: results from a meta-analysis. <i>Arthritis Research and Therapy</i> , 2015, 17, 148.	3.5	53
153	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
154	The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. <i>Rheumatology</i> , 2009, 48, 791-795.	1.9	52
155	Influence of ethnicity on childhood-onset systemic lupus erythematosus: Results from a multiethnic multicenter Canadian cohort. <i>Arthritis Care and Research</i> , 2013, 65, 152-160.	3.4	52
156	Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 850-858.	2.0	52
157	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
158	Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. <i>Rheumatology</i> , 2016, 55, 2148-2155.	1.9	52
159	Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog Scales. <i>Journal of Rheumatology</i> , 2010, 37, 1024-1028.	2.0	50
160	Osteoporosis in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 34, 678-682.	3.4	49
161	Race/ethnicity and cancer occurrence in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 53, 781-784.	6.7	49
162	The Minimally Important Difference in Clinical Practice for Patient-centered Outcomes Including Health Assessment Questionnaire, Fatigue, Pain, Sleep, Global Visual Analog Scale, and SF-36 in Scleroderma. <i>Journal of Rheumatology</i> , 2010, 37, 591-598.	2.0	49

#	ARTICLE	IF	CITATIONS
163	Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. <i>Rheumatology</i> , 2011, 50, 311-316.	1.9	49
164	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	3.4	49
165	Psoriasis and Smoking. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 221-227.	1.2	49
166	The development of systemic sclerosis classification criteria. <i>Clinical Rheumatology</i> , 2007, 26, 1401-1409.	2.2	48
167	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014, 33, 207-214.	2.2	48
168	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects. <i>Medicine (United States)</i> , 2016, 95, e4713.	1.0	48
169	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 279-284.	6.7	47
170	Quality care in seniors with new-onset rheumatoid arthritis: A Canadian perspective. <i>Arthritis Care and Research</i> , 2011, 63, 53-57.	3.4	47
171	Other Manifestations of Mixed Connective Tissue Disease. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 519-533.	1.9	46
172	The Canadian Early Arthritis Cohort (CATCH): Patients with New-onset Synovitis Meeting the 2010 ACR/EULAR Classification Criteria But Not the 1987 ACR Classification Criteria Present with Less Severe Disease Activity. <i>Journal of Rheumatology</i> , 2012, 39, 2071-2080.	2.0	46
173	Meta-analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials. <i>Arthritis Care and Research</i> , 2015, 67, 754-764.	3.4	46
174	Anti-Fibrillar Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis. <i>Journal of Rheumatology</i> , 2011, 38, 1622-1630.	2.0	45
175	Differences in Autoantibody Profiles and Disease Activity and Damage Scores Between Childhood- and Adult-Onset Systemic Lupus Erythematosus: A Meta-Analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 271-280.	3.4	45
176	The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2144-2151.	0.9	45
177	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007, 34, 501-9.	2.0	45
178	Sociodemographic and Disease Correlates of Body Image Distress among Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2012, 7, e33281.	2.5	44
179	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014, 16, 493.	3.5	44
180	Frailty Index to Measure Health Status in People with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2014, 41, 698-705.	2.0	44

#	ARTICLE	IF	CITATIONS
181	Earlier Time to Remission Predicts Sustained Clinical Remission in Early Rheumatoid Arthritis “Results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014, 41, 2161-2166.	2.0	44
182	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020, 19, 102595.	5.8	44
183	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	2.4	44
184	Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 508-13.	2.0	44
185	Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1039-1047.	5.6	44
186	Association of pruritus with quality of life and disability in systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 1489-1495.	3.4	43
187	Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease–related Interstitial Lung Diseases. <i>Journal of Rheumatology</i> , 2014, 41, 792-798.	2.0	43
188	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43
189	Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. <i>Immunotherapy</i> , 2019, 11, 737-754.	2.0	43
190	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. <i>Journal of Clinical Epidemiology</i> , 2002, 55, 488-497.	5.0	42
191	Relationship Between Disease Characteristics and Orofacial Manifestations in Systemic Sclerosis: Canadian Systemic Sclerosis Oral Health Study III. <i>Arthritis Care and Research</i> , 2015, 67, 681-690.	3.4	42
192	Calcium channel blockers for primary and secondary Raynaud's phenomenon. <i>The Cochrane Library</i> , 2017, 2017, CD000467.	2.8	42
193	Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2012, 51, 1662-1669.	1.9	41
194	Anticitrullinated Protein Antibodies and Rheumatoid Factor Fluctuate in Early Inflammatory Arthritis and Do Not Predict Clinical Outcomes. <i>Journal of Rheumatology</i> , 2013, 40, 1259-1267.	2.0	41
195	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191-197.	0.9	41
196	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	5.6	41
197	Outcome measurement in scleroderma clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , 1993, 23, 22-33.	3.4	40
198	Arthritis risk after acute bacterial gastroenteritis. <i>Rheumatology</i> , 2007, 47, 200-204.	1.9	40

#	ARTICLE	IF	CITATIONS
199	Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 402-411.	1.2	40
200	A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. <i>Genes and Immunity</i> , 2011, 12, 51-58.	4.1	40
201	Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 81-89.	3.4	40
202	<i>FC1</i> is a Genetic Determinant of Methotrexate Efficacy in Rheumatoid Arthritis: A Human Genome Epidemiologic Review and Meta-Analysis of Observational Studies. <i>Arthritis and Rheumatology</i> , 2014, 66, 1111-1120.	5.6	40
203	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 104-111.	0.4	40
204	Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. <i>Journal of Rheumatology</i> , 2002, 29, 1867-73.	2.0	40
205	Real-World Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Cost-Effectiveness Based on Number Needed to Treat to Improve Health Assessment Questionnaire. <i>Journal of Rheumatology</i> , 2009, 36, 1421-1428.	2.0	39
206	The chemokine CCL18 generates adaptive regulatory T cells from memory CD4 <sup>+</sup> T cells of healthy but not allergic subjects. <i>FASEB Journal</i> , 2010, 24, 5063-5072.	0.5	39
207	Interleukin 6 in Systemic Sclerosis and Potential Implications for Targeted Therapy. <i>Journal of Rheumatology</i> , 2012, 39, 1120-1124.	2.0	39
208	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.9	39
209	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1185-1191.	3.4	38
210	Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2018, 45, 1462-1476.	2.0	38
211	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2019, 46, 532-538.	2.0	38
212	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. <i>Rheumatology</i> , 2014, 53, 1075-1086.	1.9	37
213	The relationship of dyspnoea to function and quality of life in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 644-650.	0.9	36
214	Reduced proportions of NKT cells are present in the relatives of lupus patients and are associated with autoimmunity. <i>Arthritis Research and Therapy</i> , 2008, 10, R108.	3.5	36
215	(Not) talking about sex: a systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. <i>Rheumatology</i> , 2009, 48, 1300-1303.	1.9	36
216	Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. <i>Clinical Rheumatology</i> , 2015, 34, 1427-1433.	2.2	36

#	ARTICLE	IF	CITATIONS
217	Frequency of adverse drug reactions in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003, 30, 480-4.	2.0	36
218	Time to diagnosis in systemic sclerosis: Is sex a factor?. <i>Arthritis and Rheumatism</i> , 2009, 61, 274-278.	6.7	35
219	Development and validation of the brief "satisfaction with appearance scale for systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 1779-1786.	3.4	35
220	Anti-centromere antibodies in a large cohort of systemic sclerosis patients: Comparison between immunofluorescence, CENP-A and CENP-B ELISA. <i>Clinica Chimica Acta</i> , 2011, 412, 1937-1943.	1.1	35
221	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.	2.4	35
222	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	3.4	35
223	What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 71-74.	1.4	35
224	Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 2356-2372.	2.9	35
225	Work Disability in Scleroderma is Greater than in Rheumatoid Arthritis and is Predicted by High HAQ Scores. <i>Open Rheumatology Journal</i> , 2008, 2, 44-52.	0.2	35
226	Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. <i>Journal of Rheumatology</i> , 2002, 29, 255-60.	2.0	35
227	The lack of associations between rheumatoid arthritis and both nulliparity and infertility. <i>Seminars in Arthritis and Rheumatism</i> , 1999, 28, 342-350.	3.4	34
228	A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 421-428.	5.0	34
229	Canadian Recommendations for Use of Methotrexate in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1422-1430.	2.0	34
230	The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis. <i>Journal of Rheumatology</i> , 2016, 43, 1350-1355.	2.0	34
231	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
232	Treatment of Early Rheumatoid Arthritis: Concepts in Management. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 371-388.	3.4	33
233	Disability in Systemic Sclerosis " A Longitudinal Observational Study. <i>Journal of Rheumatology</i> , 2011, 38, 685-692.	2.0	33
234	Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster Randomized Adalimumab Trial. <i>Arthritis Care and Research</i> , 2013, 65, 1401-1409.	3.4	33

#	ARTICLE	IF	CITATIONS
235	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.7	33
236	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 807-816.	0.9	33
237	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2307-2312.	2.0	32
238	Healthcare Cost and Loss of Productivity in a Canadian Population of Patients with and without Lupus Nephritis. <i>Journal of Rheumatology</i> , 2011, 38, 658-666.	2.0	32
239	Remission in Early Rheumatoid Arthritis – A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. <i>Journal of Rheumatology</i> , 2012, 39, 1155-1158.	2.0	32
240	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015, 10, e0135327.	2.5	32
241	New Classification Criteria for Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 383-398.	1.9	32
242	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 43-53.	1.2	32
243	The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. <i>Clinical Rheumatology</i> , 2016, 35, 759-763.	2.2	32
244	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 767-774.	3.4	32
245	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1765-1770.	6.7	31
246	Time to Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis and Its Predictors: A National, Multicenter, Retrospective Cohort. <i>Journal of Rheumatology</i> , 2012, 39, 2088-2097.	2.0	31
247	Agreement with Guidelines from a Large Database for Management of Systemic Sclerosis: Results from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2012, 39, 524-531.	2.0	31
248	Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. <i>Rheumatology</i> , 2013, 52, 669-675.	1.9	31
249	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	3.4	31
250	Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 467-474.	2.0	31
251	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2197-2207.	4.2	31
252	The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 122-34.	0.8	31

#	ARTICLE	IF	CITATIONS
253	Social responsibility of hospitals: an Indian context. <i>Social Responsibility Journal</i> , 2010, 6, 268-285.	2.9	29
254	Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 1925-1930.	2.0	29
255	Effect of Age at Menopause on Disease Presentation in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 616-623.	3.4	29
256	Thinking outside the box—The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 184-189.	3.4	29
257	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. <i>Rheumatology</i> , 2016, 55, 1751-1762.	1.9	29
258	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017, 122, S14-S17.	2.9	29
259	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019, 21, 263.	3.5	29
260	Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. <i>Arthritis Research and Therapy</i> , 2019, 21, 272.	3.5	29
261	A systematic review of viral exposures as a risk for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 587-596.	3.4	29
262	The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. <i>British Journal of Rheumatology</i> , 2004, 43, 472-478.	2.3	28
263	Clinical and Serologic Factors Associated with Lupus Pleuritis. <i>Journal of Rheumatology</i> , 2010, 37, 747-753.	2.0	28
264	Is Serum Albumin a Marker of Malnutrition in Chronic Disease? The Scleroderma Paradigm. <i>Journal of the American College of Nutrition</i> , 2010, 29, 144-151.	1.8	28
265	A review of the effects of statins in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 698-705.	3.4	28
266	There is a need for new systemic sclerosis subset criteria. A content analytic approach. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 62-70.	1.1	28
267	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S23-9.	0.8	28
268	A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. <i>Journal of Rheumatology</i> , 2000, 27, 1506-12.	2.0	28
269	The frequency of and associations with hospitalization secondary to lupus flares from the 1000 Faces of Lupus Canadian cohort. <i>Lupus</i> , 2013, 22, 1341-1348.	1.6	27
270	Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. <i>Rheumatology</i> , 2011, 50, 703-708.	1.9	26



#	ARTICLE	IF	CITATIONS
271	The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis. <i>Rheumatology</i> , 2011, 50, 1125-1130.	1.9	26
272	Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1823-1830.	2.0	26
273	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor+methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000371.	3.8	26
274	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017, 12, e0189840.	2.5	26
275	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 799-805.	2.0	25
276	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.7	25
277	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. <i>Lancet Rheumatology, The</i> , 2019, 1, e23-e34.	3.9	25
278	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110262.	2.6	25
279	Scleroderma treatment differs between experts and general rheumatologists. <i>Arthritis and Rheumatism</i> , 2006, 55, 138-145.	6.7	24
280	Association of Severe Inflammatory Polyarthritis in Primary Sjögren's Syndrome: Clinical, Serologic, and HLA Analysis. <i>Journal of Rheumatology</i> , 2009, 36, 1937-1942.	2.0	24
281	The Minimally Important Difference for Patient-reported Outcomes in Spondyloarthropathies including Pain, Fatigue, Sleep, and Health Assessment Questionnaire. <i>Journal of Rheumatology</i> , 2010, 37, 816-822.	2.0	24
282	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. <i>Arthritis Care and Research</i> , 2016, 68, 673-680.	3.4	24
283	Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. <i>Rheumatology</i> , 2011, 50, 921-925.	1.9	23
284	Rates and correlates of sexual activity and impairment among women with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 340-350.	3.4	23
285	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. <i>Rheumatology International</i> , 2013, 33, 1105-1120.	3.0	23
286	Does Socioeconomic Status Affect Outcomes in Early Inflammatory Arthritis? Data from a Canadian Multisite Suspected Rheumatoid Arthritis Inception Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 46-54.	2.0	23
287	Using Optimal Test Assembly Methods for Shortening Patient-reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1704-1713.	3.4	23
288	Reports of abnormal cervical cancer screening tests in systemic sclerosis. <i>Rheumatology</i> , 2008, 48, 149-151.	1.9	22

#	ARTICLE	IF	CITATIONS
289	Influence of somatic symptoms on PHQ-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	22
290	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. <i>Journal of Rheumatology</i> , 2014, 41, 1334-1343.	2.0	22
291	Diagnosis and Management of Systemic Sclerosis: A Practical Approach. <i>Drugs</i> , 2016, 76, 203-213.	10.9	22
292	The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 685-690.	1.6	22
293	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	2.0	22
294	Association of Health-Related Quality of Life in Childhood-Onset Systemic Lupus Erythematosus With Ethnicity: Results From a Multiethnic Multicenter Canadian Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1767-1774.	3.4	21
295	Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. <i>Open Rheumatology Journal</i> , 2016, 10, 49-59.	0.2	21
296	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	1.9	21
297	Scleroderma epidemiology update. <i>Current Opinion in Rheumatology</i> , 2021, 33, 122-127.	4.3	21
298	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	2.6	21
299	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. <i>Rheumatology</i> , 2008, 47, 1367-1372.	1.9	20
300	Epidemiologic approaches to infection and immunity: the case of reactive arthritis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 386-390.	4.3	20
301	Care Gap in Patients with Early Inflammatory Arthritis with a High Fracture Risk Identified Using FRAX <sup>®</sup> . <i>Journal of Rheumatology</i> , 2010, 37, 2221-2225.	2.0	20
302	Ten-year Absolute Fracture Risk and Hip Bone Strength in Canadian Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1378-1384.	2.0	20
303	Longitudinal Study of Renal Function in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 1829-1834.	2.0	20
304	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. <i>Rheumatology</i> , 2014, 53, 988-997.	1.9	20
305	The Canadian Systemic Sclerosis Oral Health Study II: the relationship between oral and global health-related quality of life in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 692-696.	1.9	20
306	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 128-132.	0.9	20

#	ARTICLE	IF	CITATIONS
307	Early intensive treatment of clubfootxs. <i>Acta Orthopaedica</i> , 1992, 63, 183-188.	1.4	19
308	TREATMENT OF SYSTEMIC SCLEROSIS. <i>Rheumatic Disease Clinics of North America</i> , 1996, 22, 893-907.	1.9	19
309	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, S27-S34.	2.6	19
310	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. <i>Autoimmunity Reviews</i> , 2018, 17, 267-275.	5.8	19
311	Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1448-1461.	2.0	19
312	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. <i>Rheumatology</i> , 2020, 59, 398-406.	1.9	19
313	Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). <i>Autoimmunity Reviews</i> , 2020, 19, 102602.	5.8	19
314	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 852-858.	2.0	19
315	High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. <i>Arthritis and Rheumatism</i> , 2008, 59, 431-437.	6.7	18
316	What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). <i>Rheumatology International</i> , 2010, 30, 1205-1210.	3.0	18
317	The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort. <i>Open Rheumatology Journal</i> , 2013, 7, 58-63.	0.2	18
318	Factors associated with time to diagnosis in early rheumatoid arthritis. <i>Rheumatology International</i> , 2014, 34, 85-92.	3.0	18
319	Measuring the Rheumatology Workforce in Canada: A Literature Review. <i>Journal of Rheumatology</i> , 2016, 43, 1121-1129.	2.0	18
320	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
321	The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. <i>Rheumatology</i> , 2017, 56, kew474.	1.9	18
322	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.7	18
323	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019, 6, 409-419.	2.3	18
324	Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years. <i>ACR Open Rheumatology</i> , 2019, 1, 73-82.	2.1	18

#	ARTICLE	IF	CITATIONS
325	The frequency and significance of anticardiolipin antibodies in scleroderma. <i>Journal of Rheumatology</i> , 2000, 27, 1450-2.	2.0	18
326	Early Management of Newly Diagnosed Rheumatoid Arthritis by Canadian Rheumatologists: A National, Multicenter, Retrospective Cohort. <i>Journal of Rheumatology</i> , 2011, 38, 2342-2345.	2.0	17
327	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>Disability and Rehabilitation</i> , 2018, 40, 1997-2003.	1.8	17
328	Meta-Analysis of Treatment for Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020, 72, 1011-1021.	3.4	17
329	Sexual Activity and Impairment in Women with Systemic Sclerosis Compared to Women from a General Population Sample. <i>PLoS ONE</i> , 2012, 7, e52129.	2.5	17
330	Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1226-1229.	2.0	16
331	Increasing Treatment in Early Rheumatoid Arthritis Is Not Determined by the Disease Activity Score But by Physician Global Assessment: Results from the CATCH Study. <i>Journal of Rheumatology</i> , 2012, 39, 2081-2087.	2.0	16
332	Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 327-334.	1.9	16
333	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017, 69, 124-132.	3.4	16
334	ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). <i>RMD Open</i> , 2018, 4, e000738.	3.8	16
335	Squamous Cell Carcinomas in 2 Patients with Diffuse Scleroderma Treated with Mycophenolate Mofetil. <i>Journal of Rheumatology</i> , 2009, 36, 460-461.	2.0	15
336	The Use of Micronutrient Supplements Is Not Associated with Better Quality of Life and Disease Activity in Canadian Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 87-90.	2.0	15
337	Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2013, 40, 447-454.	2.0	15
338	Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor. <i>PLoS ONE</i> , 2014, 9, e100035.	2.5	15
339	Reduction in Serum Uric Acid may be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016, 9, CMAMD.S38092.	1.2	15
340	Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?. <i>Journal of Rheumatology</i> , 2018, 45, 827-834.	2.0	15
341	Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 1245-1250.	3.4	15
342	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. <i>Rheumatology</i> , 2019, 58, 1393-1399.	1.9	15

#	ARTICLE	IF	CITATIONS
343	Increased pigmentation in scleroderma. <i>Journal of Rheumatology</i> , 1996, 23, 1912-6.	2.0	15
344	Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. <i>Arthritis and Rheumatism</i> , 2008, 59, 706-713.	6.7	14
345	Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan: Table 1. <i>Annals of the Rheumatic Diseases</i> . 2010, 69, 2055-2056.	0.9	14
346	Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain. <i>Journal of Rheumatology</i> , 2011, 38, 2581-2587.	2.0	14
347	Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations. <i>Journal of Rheumatology</i> , 2013, 40, 1121-1126.	2.0	14
348	Cross-Language Measurement Equivalence of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis: A Comparison of Canadian and Dutch Patients. <i>PLoS ONE</i> , 2013, 8, e53923.	2.5	14
349	Editorial: "Weighing in" on the Framingham Osteoarthritis Study: Measuring Biomechanical and Metabolic Contributions to Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1127-1130.	5.6	14
350	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1715-1724.	1.9	14
351	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. <i>Autoimmunity Reviews</i> , 2020, 19, 102659.	5.8	14
352	Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 53-60.	5.6	14
353	Treatment of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 1993, 5, 792-801.	4.3	13
354	Canadian Variation by Province in Rheumatoid Arthritis Initiating Anti-Tumor Necrosis Factor Therapy: Results from the Optimization of Adalimumab Trial. <i>Journal of Rheumatology</i> , 2010, 37, 2469-2474.	2.0	13
355	Does cigarette smoking mitigate the severity of skin disease in systemic sclerosis?. <i>Rheumatology International</i> , 2013, 33, 943-948.	3.0	13
356	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e91979.	2.5	13
357	Comprehensive Arthritis Referral Study "Phase 2: Analysis of the Comprehensive Arthritis Referral Tool. <i>Journal of Rheumatology</i> , 2014, 41, 1980-1989.	2.0	13
358	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015, 17, 343.	3.5	13
359	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2016, 56, kew441.	1.9	13
360	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	3.4	13

#	ARTICLE	IF	CITATIONS
361	Patient-Reported Outcome Measures in Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 301-316.	1.9	13
362	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 456-464.	2.0	13
363	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	1.9	13
364	Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. <i>BMJ Open</i> , 2019, 9, e024010.	1.9	13
365	Evolving patterns of reactive arthritis. <i>Clinical Rheumatology</i> , 2019, 38, 2083-2088.	2.2	13
366	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	0.6	13
367	A randomized double blind trial of verbal NSAID education compared to verbal and written education. <i>Journal of Rheumatology</i> , 1998, 25, 771-5.	2.0	13
368	The Association Between Disease Activity and Duration in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2299-2306.	2.0	12
369	Altered Salivary Redox Homeostasis in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 1858-1863.	2.0	12
370	Canadian Recommendations for Clinical Trials of Pharmacologic Interventions in Rheumatoid Arthritis: Inclusion Criteria and Study Design: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 2095-2104.	2.0	12
371	Modeling smoking in systemic sclerosis: A comparison of different statistical approaches. <i>Arthritis Care and Research</i> , 2011, 63, 570-578.	3.4	12
372	Medication Use in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 271-274.	2.0	12
373	Effect of Rheumatologist Education on Systematic Measurements and Treatment Decisions in Rheumatoid Arthritis: The Metrix Study. <i>Journal of Rheumatology</i> , 2012, 39, 2247-2252.	2.0	12
374	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1510-1518.	2.0	12
375	Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019, 71, 620-628.	3.4	12
376	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019, 46, 166-175.	2.0	12
377	Incidence and prevalence of giant cell arteritis in Ontario, Canada. <i>Rheumatology</i> , 2020, 59, 3250-3258.	1.9	12
378	Results From the 2020 Canadian Rheumatology Association's Workforce and Wellness Survey. <i>Journal of Rheumatology</i> , 2022, 49, 635-643.	2.0	12

#	ARTICLE	IF	CITATIONS
379	Antimitochondrial Antibodies and Their Significance in Diffuse and Limited Scleroderma. <i>Journal of Clinical Rheumatology</i> , 1999, 5, 206-209.	0.9	11
380	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 654-662.	5.0	11
381	Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2014, 53, 482-490.	1.9	11
382	There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014, 81, 347-351.	1.6	11
383	Systemic Sclerosis Classification: A Rose by Any Other Name Would Smell As Sweet?. <i>Journal of Rheumatology</i> , 2015, 42, 11-13.	2.0	11
384	Development and Validation of the Body Concealment Scale for Scleroderma. <i>Arthritis Care and Research</i> , 2016, 68, 1158-1165.	3.4	11
385	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. <i>Rheumatology</i> , 2017, 56, 1111-1122.	1.9	11
386	Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. <i>RMD Open</i> , 2018, 4, e000578.	3.8	11
387	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Journal of Rheumatology</i> , 2019, 46, 1605-1613.	2.0	11
388	Encounters with Rheumatologists in a Publicly Funded Canadian Healthcare System: A Population-based Study. <i>Journal of Rheumatology</i> , 2020, 47, 468-476.	2.0	11
389	Evaluation of Rheumatology Workforce Supply Changes in Ontario, Canada, from 2000 to 2030. <i>Healthcare Policy</i> , 2021, 16, 119-135.	0.6	11
390	Healthcare utilization and economic burden in systemic sclerosis: a systematic review. <i>Rheumatology</i> , 2022, 61, 3123-3131.	1.9	11
391	Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S38-43.	0.8	11
392	Cardiovascular disease after <i>Escherichia coli</i> O157:H7 gastroenteritis. <i>Cmaj</i> , 2013, 185, E70-E77.	2.0	10
393	Psychological Distress in Out-Patients Assessed for Chronic Pain Compared to Those with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016, 2016, 1-7.	1.8	10
394	Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. <i>Arthritis Care and Research</i> , 2016, 68, 1143-1149.	3.4	10
395	Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report. <i>BMC Cancer</i> , 2016, 16, 243.	2.6	10
396	High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. <i>Arthritis Care and Research</i> , 2018, 70, 842-850.	3.4	10

#	ARTICLE	IF	CITATIONS
397	Mentoring women in medicine: a personal perspective. <i>Lancet, The</i> , 2018, 391, 520-521.	13.7	10
398	Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 535-541.	2.1	10
399	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 1104-1111.	3.4	10
400	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology, The</i> , 2020, 2, e185-e194.	3.9	10
401	Feminization of the Rheumatology Workforce: A Longitudinal Evaluation of Patient Volumes, Practice Sizes, and Physician Remuneration. <i>Journal of Rheumatology</i> , 2021, 48, 1090-1097.	2.0	10
402	Assessment of reproductive history in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 1661-1664.	6.7	9
403	The Temporal Relationship of Raynaud's Phenomenon and Features of Connective Tissue Disease in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 2329-2333.	2.0	9
404	OP0054...Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 48 Data from the Fascinate Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 87.2-88.	0.9	9
405	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. <i>Clinical Rheumatology</i> , 2017, 36, 373-379.	2.2	9
406	Management of Raynaud's phenomenon in systemic sclerosis—a practical approach. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 102-110.	1.7	9
407	Planning for the Rheumatologist Workforce. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 142-146.	0.9	9
408	An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1421-1427.	3.4	9
409	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	2.6	9
410	Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 197-202.	5.6	9
411	Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study. <i>Rheumatology</i> , 2022, 61, 606-616.	1.9	9
412	Stress in patients diagnosed with rheumatoid arthritis compared to chronic pain.. <i>Rehabilitation Psychology</i> , 2017, 62, 571-579.	1.3	9
413	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e102897.	2.5	9
414	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology, The</i> , 2021, 3, e844-e854.	3.9	9



#	ARTICLE	IF	CITATIONS
415	The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 499-505.	3.4	8
416	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	3.4	8
417	An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. <i>Rheumatology</i> , 2020, 59, 1522-1528.	1.9	8
418	A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2022, 4, 57-64.	2.1	8
419	Challenges of Perceived Self-Management in Lupus. <i>Arthritis Care and Research</i> , 2022, 74, 1113-1121.	3.4	8
420	The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. <i>Medical Science Monitor</i> , 2008, 14, CR604-10.	1.1	8
421	Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study. <i>Rheumatology</i> , 2014, 53, 1830-1834.	1.9	7
422	Social persuasion in rheumatology: a randomized trial of testimonials on television in the rheumatology clinic waiting room to increase attendance for multidisciplinary education. <i>Rheumatology International</i> , 2014, 34, 903-907.	3.0	7
423	Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 2023-2028.	2.0	7
424	Mood, Disability, and Quality of Life among a Subgroup of Rheumatoid Arthritis Individuals with Experiential Avoidance and Anxiety Sensitivity. <i>Pain Research and Management</i> , 2016, 2016, 1-7.	1.8	7
425	Emerging drugs and therapeutics for systemic sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 421-430.	2.4	7
426	The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 364.	1.9	7
427	Flibanserin. <i>Journal of Pharmacy Practice</i> , 2017, 30, 256-260.	1.0	7
428	Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. <i>Rheumatology</i> , 2020, 59, 568-574.	1.9	7
429	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.7	7
430	Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). <i>RMD Open</i> , 2021, 7, e001673.	3.8	7
431	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16799.	1.0	7
432	Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2020, 39, 963-965.	2.2	7

#	ARTICLE	IF	CITATIONS
433	Demographic and Clinical Factors Associated with Physician Service Use in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 96-98.	2.0	6
434	New evidence-based guidelines for treating SSc. <i>Nature Reviews Rheumatology</i> , 2009, 5, 300-302.	8.0	6
435	The sensitivity and specificity of pain diagrams in rheumatic disease referrals. <i>Rheumatology</i> , 2012, 51, 1093-1098.	1.9	6
436	Measuring flares in systemic lupus erythematosus. <i>Rheumatology</i> , 2014, 53, 2134-2135.	1.9	6
437	Health Literacy Rates in a Population of Patients with Rheumatoid Arthritis in Southwestern Ontario. <i>Journal of Rheumatology</i> , 2015, 42, 1610-1615.	2.0	6
438	How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project. <i>Journal of Rheumatology</i> , 2016, 43, 788-798.	2.0	6
439	The frequency of uveitis in patients with adult versus childhood spondyloarthritis. <i>RMD Open</i> , 2020, 6, e001196.	3.8	6
440	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	2.0	6
441	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2013, 2013, 1119.	0.2	6
442	A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 24-30.	0.8	6
443	Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 799-803.	0.8	6
444	The Relation of the Petersen System of Grounding Power Networks to Inductive Effects in Neighboring Communication Circuits. <i>Bell System Technical Journal</i> , 1922, 1, 39-59.	0.6	5
445	Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 232-233.	1.1	5
446	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1156-1162.	2.0	5
447	Dispositional Affect in Unique Subgroups of Patients with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016, 2016, 1-9.	1.8	5
448	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies" Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 149-152.	0.3	5
449	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019, 1, 471-479.	2.1	5
450	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2019, 71, 1300-1303.	3.4	5

#	ARTICLE	IF	CITATIONS
451	Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2019, 9, e029542.	1.9	5
452	How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology. <i>Immunotherapy</i> , 2020, 12, 1115-1119.	2.0	5
453	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020, 22, 132.	3.5	5
454	Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial. <i>Medical Science Monitor</i> , 2012, 18, P117-PI20.	1.1	5
455	Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor. <i>Open Rheumatology Journal</i> , 2014, 8, 73-76.	0.2	5
456	Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves. <i>ISRN Rheumatology</i> , 2011, 2011, 1-6.	1.9	5
457	The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. <i>Rheumatology</i> , 2010, 49, 1616-1617.	1.9	4
458	Survival is improving in systemic sclerosis: true or false?. <i>Rheumatology</i> , 2012, 51, 959-961.	1.9	4
459	Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort. <i>Rheumatology International</i> , 2013, 33, 457-465.	3.0	4
460	Ottawa, Ontario, Canada, February 13-16, 2013. <i>Journal of Rheumatology</i> , 2013, 40, 950-1025.	2.0	4
461	Arthritis Clinical Trials at a Crossroad. <i>Journal of Rheumatology</i> , 2015, 42, 14-17.	2.0	4
462	TNF inhibitors and cardiovascular risk management in RA. <i>Nature Reviews Rheumatology</i> , 2016, 12, 317-318.	8.0	4
463	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating "not applicable" responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2018, 8, e018641.	1.9	4
464	Association of Arthritis Onset with Influenza: Analysis of the Canadian Early Inflammatory Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2019, 1, 63-69.	2.1	4
465	Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort. <i>ACR Open Rheumatology</i> , 2019, 1, 614-619.	2.1	4
466	Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists. <i>Joint Bone Spine</i> , 2020, 87, 588-595.	1.6	4
467	Giant Calcinosis in Dermatomyositis and Scleroderma Overlap. <i>Arthritis and Rheumatology</i> , 2020, 72, 1236-1236.	5.6	4
468	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	3.4	4

#	ARTICLE	IF	CITATIONS
469	Immunosuppression use in early systemic sclerosis may be increasing over time. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 33-41.	1.7	4
470	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. <i>Journal of Rheumatology</i> , 2021, 48, 1427-1434.	2.0	4
471	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	1.6	4
472	Measuring the Impact of <scp>MyLupusGuide</scp> in Canada: Results of a Randomized Controlled Study. <i>Arthritis Care and Research</i> , 2023, 75, 529-539.	3.4	4
473	Calcium channel blockers for Raynaud's phenomenon in patients with scleroderma. <i>The Cochrane Library</i> , 1996, , .	2.8	3
474	Validity of Self-Reported Comorbidities in Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2009, 36, 1477-1480.	2.0	3
475	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	3.4	3
476	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	2.0	3
477	Progress and Priorities in Systemic Sclerosis: The Next 10 Years â€” Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.7	3
478	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	4.3	3
479	Reflections on the EULAR recommendations for the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 134-136.	8.0	3
480	Pulmonary arterial hypertension in scleroderma: care gaps in screening. <i>Arthritis Research and Therapy</i> , 2017, 19, 128.	3.5	3
481	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 737-741.	3.4	3
482	Randomized Trials, Meta-Analyses, and Systematic Reviews. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 295-305.	1.9	3
483	Editorial: Safety of Tumor Necrosis Factor Inhibitors in Pregnancy. <i>Arthritis and Rheumatology</i> , 2018, 70, 1359-1363.	5.6	3
484	Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiativeâ€™a rheumatoid arthritis cohort. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 95-103.	5.0	3
485	Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. <i>Journal of Rheumatology</i> , 2019, 46, 874-886.	2.0	3
486	Increased mortality for individuals with Giant Cell Arteritis: a populationâ€™based study. <i>Arthritis Care and Research</i> , 2021, , .	3.4	3

#	ARTICLE	IF	CITATIONS
487	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1383-1391.	2.3	3
488	Pain and Self-Efficacy Among Patients With Systemic Sclerosis. <i>Nursing Research</i> , 2021, 70, 334-343.	1.7	3
489	Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma patient-centred Intervention Network (SPIN) Cohort Study. <i>BMJ Open</i> , 2020, 10, e037639.	1.9	3
490	Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. <i>Clinical and Investigative Medicine</i> , 1995, 18, 1-10.	0.6	3
491	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	1.2	3
492	Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	3
493	Convergence Paralysis as a Manifestation of Polyarteritis Nodosa. <i>Canadian Journal of Neurological Sciences</i> , 2006, 33, 423-425.	0.5	2
494	Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 390-391.	1.1	2
495	THU0412â€¦Cardiovascular Outcomes in Patients with Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analyses: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 324.2-325.	0.9	2
496	Drug interventions versus placebo for the treatment of Raynaudâ€™s phenomenon: generic protocol. <i>The Cochrane Library</i> , 2015, , .	2.8	2
497	Response to: â€œDrugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?â€™ by Dr Boers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e34-e34.	0.9	2
498	FRIO066â€¦The 28-Joint Disease Activity Score (DAS28) Using C-Reactive Protein Yields Lower Thresholds Compared To Conventional DAS28 with Erythrocyte Sedimentation Rate in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 449.3-450.	0.9	2
499	Trial methodology in scleroderma: Avoiding a shot in the dark. <i>Rheumatology</i> , 2017, 56, v1-v3.	1.9	2
500	Editorial: Bench to Bedsideâ€”and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe. <i>Arthritis and Rheumatology</i> , 2018, 70, 155-156.	5.6	2
501	The contemporary management of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 573-582.	3.0	2
502	What is the best treatment for early rheumatoid arthritis?. <i>Rheumatology</i> , 2019, 58, 2086-2088.	1.9	2
503	OP0315â€¦ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS. , 2019, , .		2
504	OP0183â€¦EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
505	Prescribing Opioids for Severe Hip and Knee Osteoarthritis Varies Widely in the United States: The Devil Is in the Details. <i>Arthritis and Rheumatology</i> , 2019, 71, 659-661.	5.6	2
506	Would a "Rosendo"™ by Another Name Smell as Sweet? Gender Disparity in Academic Rank and Publications in Rheumatology. <i>Arthritis and Rheumatology</i> , 2021, 73, 5-8.	5.6	2
507	Estimating Benefits from Immunosuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2014, 04, 248-253.	0.2	2
508	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2003, , 1339-48.	0.2	2
509	A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S40-6.	0.8	2
510	Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017-2021: Results From the Canadian Early Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2022, 4, 566-573.	2.1	2
511	Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. <i>ACR Open Rheumatology</i> , 2022, 4, 254-258.	2.1	2
512	Sexual function in women with systemic sclerosis: Comment on the article by Schouffoer et al. <i>Arthritis Care and Research</i> , 2010, 62, 1200-1200.	3.4	1
513	Observational Data to Study Medication Outcomes in Systemic Sclerosis: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 575.2-577.	2.0	1
514	FRIO241...Association of gastroesophageal factors and progression of interstitial lung disease in the canadian scleroderma research group (CSRG); a large, multi-center database.. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 395.3-396.	0.9	1
515	A153: Long-term Outcomes of Childhood-Onset Systemic Lupus Erythematosus in Adulthood. <i>Arthritis and Rheumatology</i> , 2014, 66, S198.	5.6	1
516	Response to: "Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?"™ by Jan Damoiseaux. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e30-e30.	0.9	1
517	Psychological Distress in Out-Patients Assessed for Chronic Pain Compared to Those with Rheumatoid Arthritis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2015, 96, e65.	0.9	1
518	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1053-1054.	3.4	1
519	Predicting improvement in diffuse scleroderma: lessons learnt. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1741-1742.	0.9	1
520	Editorial: The Effect of Ethnicity on Cardiovascular Outcomes in Systemic Lupus Erythematosus Is Perhaps Not a Paradox. <i>Arthritis and Rheumatology</i> , 2017, 69, 1707-1709.	5.6	1
521	A randomized, single-blinded cross-over trial of ischemic preconditioning in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 213-220.	1.7	1
522	OP0068...ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS" RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL. , 2019, ,		1

#	ARTICLE	IF	CITATIONS
523	SAT0352â€¦...THE FREQUENCY OF OCULAR MANIFESTATIONS IN PATIENTS WITH ADULT VS. CHILDHOOD SPONDYLOARTHRITIS. , 2019, , .		1
524	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. RMD Open, 2019, 5, e000931.	3.8	1
525	A cluster of non-tuberculosis mycobacterial infections in patients with connective tissue diseases. Medicina ClÃnica, 2020, 154, 468-469.	0.6	1
526	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply. Rheumatology, 2020, 59, 1783-1784.	1.9	1
527	Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake. Journal of Rheumatology, 2020, 47, 164-165.	2.0	1
528	Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). Rheumatology, 2021, 60, 717-727.	1.9	1
529	Authorsâ€™ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in Therapy, 2021, 38, 2750-2756.	2.9	1
530	Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). Arthritis Care and Research, 0, , .	3.4	1
531	Osteoporosis and osteonecrosis in systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 3-11.	0.1	1
532	Systemic Sclerosis. , 2013, , 955-969.		1
533	SAT0513â€¦...Progressive skin fibrosis is associated with a decline in lung function and poorer survival in patients with diffuse cutaneous systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis. , 2018, , .		1
534	The Canadian Consensus Working Groupâ€™s Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. Contemporary Cardiology, 2020, , 137-150.	0.1	1
535	Treatment of osteoarthritis of the hip and knee: a comparison of NSAID use in patients for whom surgery was and was not recommended. Clinical and Experimental Rheumatology, 2004, 22, 171-6.	0.8	1
536	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. Clinical and Experimental Rheumatology, 2021, 39, 874-878.	0.8	1
537	Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers. Arthritis Care and Research, 2022, , .	3.4	1
538	Renal calcification. , 0, , 276-281.		0
539	Frequency of adverse drug reactions (ADRS) in SLE. Clinical Pharmacology and Therapeutics, 2003, 73, P54-P54.	4.7	0
540	Systemic Sclerosis (Scleroderma) and Raynaudâ€™s Phenomenon. , 2009, , 77-95.		0

#	ARTICLE	IF	CITATIONS
541	Medication Use in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 667-667.	2.0	0
542	Issues in Clinical Trial Design. , 2012, , 651-660.		0
543	To screen or not to screen for PAH in connective tissue diseases?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 699-700.	8.0	0
544	Updated systemic sclerosis criteria improve disease classification. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 609-609.	0.5	0
545	Is having rheumatoid arthritis a fate worse than death?. <i>Rheumatology</i> , 2013, 52, 767-768.	1.9	0
546	OP0257â€¦IL-6 in scleroderma; potential implications for targeted therapy: A systematic analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 143.1-143.	0.9	0
547	FRI0187â€¦The effectiveness of abatacept in a large RA real world database including durability and changes in haq over time: Post DMARDs and post TNF:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 375.3-376.	0.9	0
548	SAT0101â€¦Das does not predict increasing treatment in early rheumatoid arthritis (ERA): Results from the catch study:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 504.2-504.	0.9	0
549	FRI0375â€¦A Delphi Exercise for Treatment Algorithms for Systemic Lupus Erythematosus: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 522.3-523.	0.9	0
550	Lacunes dans la prise en charge de lâ€™ostÃ©oporose chez les patients atteints de polyarthrite rhumatoÃ©de. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 413-417.	0.0	0
551	SAT0587â€¦A Comparative Study of Rheumatology Specialist Training across UK and Canada. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 802.2-802.	0.9	0
552	FRI0371â€¦A Comparison of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) TRIAL Design: Ways to Improve Positive Trials in Sle:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 521.1-521.	0.9	0
553	OP0200â€¦Thromboembolism in Rheumatology: Investigation of the Risks of Deep Vein Thrombosis and Pulmonary Embolism in Inflammatory Arthritis, Connective Tissue Diseases, Vasculitis and Myositis:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138.2-138.	0.9	0
554	AB0251â€¦The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) Serology on Outcomes in Early Rheumatoid Arthritis: Results from Catch (Canadian Early Arthritis Cohort): Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 886.2-887.	0.9	0
555	SAT0119â€¦Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients â€œ Data from the Ontario Best Practices Research Initiative (OBRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 693.2-693.	0.9	0
556	Lessons learned from Canadian databases in RA, SLE and systemic sclerosis: highlights from the Canadian Rheumatology Association Annual Scientific Meeting. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 135-137.	0.3	0
557	THU0337â€¦Worse Disease Trajectory in Early RA Patients is Associated with Lower Improvements in Health Related Quality of Life; Results from a Multicenter Early RA Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 317.2-318.	0.9	0
558	Arteriogram of a 51-Year-Old Patient with Mixed Features of Mixed Connective Tissue Diseases. <i>Rheumatology (Sunnyvale, Calif)</i> , 2015, s6, .	0.3	0



#	ARTICLE	IF	CITATIONS
559	SAT0347â€¦Comparisons of Reporting and Level of Agreement of Co-Morbidities Ascertained from Rheumatologists, Patients and Health Administrative Data: A Data Linkage Study Among Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 784.2-785.	0.9	0
560	Drug Treatment of Raynaudâ€™s Phenomenon. , 2015, , 315-337.		0
561	Dr. Roubille, et al reply. <i>Journal of Rheumatology</i> , 2016, 43, 993-994.	2.0	0
562	FRI0269â€¦Diffuse Cutaneous Systemic Sclerosis (dcSSc) Referral and Diagnosis: Results of A Survey of Healthcare Providers. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 532.1-532.	0.9	0
563	AB0206â€¦Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from The Ontario Best Practice Research Initiatives Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 967.3-968.	0.9	0
564	OPO173â€¦How Much of A Barrier Is Excess Weight and Smoking for Achieving Sustained Remission in Early RA? Results from The Canadian Early Arthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 121.2-121.	0.9	0
565	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1385-1386.	3.4	0
566	FRI0375â€¦Real-life treatment strategies for systemic sclerosis according to experts. , 2017, , .		0
567	SAT0039â€¦Large tender joints have the greatest impact on longitudinal trajectories of function in early rheumatoid arthritis. , 2017, , .		0
568	Validation of Self-Reported Cardiovascular Disease and Associated Co- Morbidities in a Large Canadian Cohort of Early Inflammatory Arthritis. <i>Rheumatology (Sunnyvale, Calif)</i> , 2017, 07, .	0.3	0
569	THU0106â€¦Converting patient-reported outcome measures of fatigue and pain to promis scores: data from phase 3 baricitinib rheumatoid arthritis trials. , 2018, , .		0
570	FRI0013â€¦Converting patient-reported physical function outcomes scores to promis metric scores in phase 3 trials of baricitinib in rheumatoid arthritis. , 2018, , .		0
571	How low can we go for continued dosing of rituximab in rheumatoid arthritis?. <i>Lancet Rheumatology, The</i> , 2019, 1, e134-e135.	3.9	0
572	FRI0303â€¦THE EFFECTS OF RIOCIQUAT ON RAYNAUDâ€™S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		0
573	FRI0069â€¦FREQUENCY OF EYE INVOLVEMENT IN INFLAMMATORY ARTHRITIS AND CONNECTIVE TISSUE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. , 2019, , .		0
574	THU0658â€¦WHO IS AT RISK FOR PERSISTENT FATIGUE IN THE FIRST YEAR OF RA? CHARACTERISTICS OF PATIENTS WITH PERSISTENT FATIGUE IN THE FIRST YEAR BY SEX IN THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). , 2019, , .		0
575	OPO269â€¦HPR PATTERNS OF FATIGUE AND PREDICTORS OF SIGNIFICANT IMPROVEMENT IN THE 1ST YEAR OF RA: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH). , 2019, , .		0
576	THU0692â€¦OCULAR MANIFESTATIONS IN BEHCETâ€™S DISEASE MAY BE MORE COMMON IN CHILDREN THAN ADULTS: RESULTS OF A SYSTEMATIC REVIEW. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
577	Reply. Arthritis and Rheumatology, 2019, 71, 834-835.	5.6	0
578	Immunoglobulin G<sub>4</sub>-related disease as a mimicker of granulomatosis with polyangiitis: a case report. Scandinavian Journal of Rheumatology, 2020, 49, 163-164.	1.1	0
579	An Update of Outcome Measures in Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 110-133.	3.4	0
580	Comment on: Incidence and prevalence of giant cell arteritis in Ontario, Canada: reply. Rheumatology, 2020, 59, e123-e124.	1.9	0
581	European consensus statements for interstitial lung disease in systemic sclerosis. Lancet Rheumatology, The, 2020, 2, e318-e319.	3.9	0
582	Metrics and Outcomes of Systemic Lupus Erythematosus in Clinical Practice. , 2021, , 391-402.		0
583	Pertinence des tests de laboratoire dans le diagnostic des rhumatismes inflammatoires chez des patients nouvellement orientés vers un rhumatologue. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 208-215.	0.0	0
584	Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!. Arthritis and Rheumatology, 2021, 73, 1124-1126.	5.6	0
585	Reply. Arthritis and Rheumatology, 2022, 74, 178-180.	5.6	0
586	Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database. Current Rheumatology Reviews, 2021, 17, 349-359.	0.8	0
587	Measurement in Scleroderma Clinical Trials. , 2000, , 183-203.		0
588	SEQUENCE OF VARIABLES IN THE DIMENSIONAL SET. , 2007, , 381-400.		0
589	A Middle-Aged Male Scleroderma Patient Who Can No Longer Perform His Occupation. , 2011, , 281-292.		0
590	Skin Manifestations and Musculoskeletal Disease in SSc. , 2014, , 23-36.		0
591	PROMs for Systemic Sclerosis (Scleroderma). , 2016, , 287-307.		0
592	A Needs-Based Rheumatologist Education Program on Treating to Target in Psoriatic Arthritis and Spondyloarthritis: Insights and Challenges. Open Journal of Rheumatology and Autoimmune Diseases, 2017, 07, 53-64.	0.2	0
593	SAT0073â€¦.Acpa and rf as predictors of sustained clinical remission in rheumatoid arthritis patients: results from the ontario best practices research initiative (OBRI). , 2018, , .		0
594	AB0240â€¦...Reduction in fatigue and pain are associated with improved work productivity in patients with ra. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
595	OP0106â€¦Who is not reaching remission in early ra and why? predictors for persistent disease activity in the first year differ in men and women and are related to lifestyle and treatment. , 2018, , .		0
596	THU0676â€¦A systematic review and meta-analysis of viral exposures as a risk factor for rheumatoid arthritis. , 2018, , .		0
597	SAT0080â€¦Secular trends prior to-and after dissemination of best practice recommendations showed earlier intensified medication strategies and improved outcomes in canadians with early inflammatory arthritis. , 2018, , .		0
598	SAT0112â€¦Guideline-based care improves outcomes that matter to patients: tighter control, less suffering, and greater well-being over the past decade in canadian ra patients. , 2018, , .		0
599	THU0653â€¦Changes in rheumatology provision and practice in a publicly-funded single payer healthcare system. , 2018, , .		0
600	Arthritis in Systemic Sclerosis. In Clinical Practice, 2021, , 339-362.	0.0	0
601	The erratic C-reactive protein: a novel outcome measure for longitudinal disease activity in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
602	IgG4-Related Disease, A Single-Center Experience. Journal of Clinical Rheumatology, 2018, 27, 1.	0.9	0
603	To choose or not? The value of discrete-choice experiments in rheumatology. Nature Reviews Rheumatology, 0, , .	8.0	0